Prism Medico & Pharmacy Limited has filed a regulatory compliance intimation with stock exchanges regarding its non-convertible securities position for the upcoming quarter. The company has confirmed that no such securities exist with payable obligations during the specified period.

Regulatory Compliance Filing

The company submitted its intimation on 30th March, 2026, addressing both BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI). This filing was made pursuant to Regulation 57(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Non-Convertible Securities Status

Prism Medico and Pharmacy Limited has declared that it has not issued any non-convertible securities for which interest, dividend, or principal amounts shall be payable during the quarter beginning from 01st April, 2026 and ending on 30th June, 2026. This intimation ensures compliance with regulatory requirements for listed companies regarding their debt securities obligations.

Company Information

The filing was signed by Davender Singh, Director of the company, bearing DIN: 09447213. The company is incorporated under CIN: L24100HP2002PLC009299 with its registered office located at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Prism medico & pharmacy Limited has issued a regulatory clarification to stock exchanges regarding significant movement in its security price, attributing the fluctuations to market-driven speculation rather than any undisclosed material information.

Regulatory Disclosure Details

The company submitted its clarification on February 27, 2026, to both BSE Limited and Metropolitan Stock Exchange of India Limited (MSEI) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in response to exchange queries about recent price movements in the company's securities.

Management's Position on Price Movement

The company management emphasized that all material information bearing on operations and performance has been regularly disclosed to stock exchanges in a timely and accurate manner. The disclosure confirms compliance with corporate governance principles outlined in Regulation 4 of SEBI regulations and related circulars.

According to the company's statement, the price movement is purely attributed to:

• Market conditions and market-driven factors
• Speculative trading activities
• Factors beyond management control

Key Compliance Confirmations

The company provided several important confirmations in its regulatory filing:

Ongoing Regulatory Commitment

Prism Medico and Pharmacy Limited reiterated its commitment to maintaining transparency with stock exchanges and investors. The company confirmed it will continue to inform exchanges about any price-sensitive information as mandated under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The clarification was signed by Davender Singh, Director of the company (DIN: 09447213), emphasizing the management's direct involvement in ensuring regulatory compliance and transparent communication with stakeholders.